Megadalton Solutions Fast-tracks Commercial Availability of Analytical Support for Gene Therapy and COVID Therapeutics

Bloomington, IN – October TBD – Megadalton Solutions, Inc., is an early-stage biotech company commercializing technology developed in Martin Jarrold’s research group at Indiana University. Megadalton Solutions specializes in large molecule analysis by Charge Detection Mass Spectrometry (CDMS). CDMS extends the precision of mass spectrometry to molecules in the megadalton and gigadalton size regime, and has been successfully employed by Martin Jarrold to analyze gene delivery platforms important for rare diseases and a potential COVID-19 vaccine.

The COVID-19 pandemic spurred innovation as Megadalton and the Jarrold research group collaborated on a number of projects that target next generation vaccine therapeutics. Megadalton’s essential research continued throughout the spring 2020 research hibernation and Research Scientist Ben Draper (Ph.D., 2018, M. Jarrold group) indicates upcoming publications regarding adeno-associated virus (AAV), adenovirus, the SARS-COV-2 spike protein, and existing commercially available vaccines all measured by CDMS are in review or in preparation.

Started in 2018, Megadalton Solutions has secured Phase I and Phase II SBIR grants from the NIH as well as attracting a collaboration from Waters Corporation (NYSE: WAT) to bring CDMS technology to a broader set of applications and potential customers in biopharma.

Waters became a strategic investor in Megadalton Solutions in 2020. Through their established co-development agreement, Waters will integrate Megadalton’s CDMS technology within its new Immerse Cambridge innovation and research lab, using it in collaborative engagements with local academic and commercial pharma and biopharma partners in the New England scientific community.

“We’re thrilled that Waters, an industry leader in mass spectrometry and liquid chromatography, recognizes the potential of CDMS as an important tool to extend the accessible mass range of mass spectrometry. Waters’ interest in cell and gene therapy separations create a nice harmony with our work,” said Martin F. Jarrold, CEO at Megadalton Solutions, Inc. “We are pleased to have them as a strategic investor and look forward to our future collaboration to develop in this space.”

About Megadalton Solutions
Megadalton Solutions is an early-stage biotechnology company developing CDMS based assays for the analysis of large molecules such as gene therapies. Gene based therapies represent the next generation of medicine, and many of the platforms utilized fall outside the size range of conventional mass spectrometry. CDMS overcomes the limitations of conventional mass spectrometry to allow for the precision of mass spectrometry to be extended to this new class of therapeutics. For more information go to: